'Epi' tools aim to ease forecasting

Share this article:
Market forecasting is never an easy process, but Datamonitor believes its new epidemiological offering can help.

The UK firm launched two tools to help accurately determine current and future disease burdens: EpiFocus, an epidemiological database, and EpiReport, which interprets trends and provides background to the disease epidemiology. Combined with treatment data, epidemiological figures can be used to forecast unmet market need, typically through a bottom-up forecast.

“It's really fundamental to get good epi. data right at the beginning of your forecasting,” said Sarah Dougan, MA, MSc, senior member of the Datamonitor epidemiology team, which was formed last year and is available for client consultations.

The first installment contains detailed segmentation of the breast cancer population, with the number of treatable cases in each of the seven major markets forecast over a 10-year period. Datamonitor plans to release data on other cancers—NSCL, colon and rectal—throughout this year and next.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...